We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+26.99%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$12.5B
AUM Growth
+$844M
Cap. Flow
-$1.62B
Cap. Flow %
-12.95%
Top 10 Hldgs %
33.14%
Holding
137
New
32
Increased
25
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$331M
2
AON icon
Aon
AON
+$321M
3
WUBA
58.com Inc
WUBA
+$256M
4
BMY icon
Bristol-Myers Squibb
BMY
+$217M
5
TIF
Tiffany & Co.
TIF
+$191M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$1.65B
2
CI icon
Cigna
CI
+$142M
3
FIS icon
Fidelity National Information Services
FIS
+$135M
4
GD icon
General Dynamics
GD
+$132M
5
WAB icon
Wabtec
WAB
+$113M

Sector Composition

Rank Sector Weight
1 Healthcare 43.19%
2 Communication Services 20.54%
3 Technology 10.42%
4 Financials 7.52%
5 Consumer Discretionary 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
51
Grifois
GRFS
$5.44B
$56.8M 0.45%
3,113,222
– –
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
$56.7M 0.45%
+900,000
New +$49.5M
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
$54M 0.43%
2,000,000
-250,000
-11% -$6.9M
ZNTL icon
54
Zentalis Pharmaceuticals
ZNTL
$363M
$47.6M 0.38%
+991,174
New +$38M
GBIO
55
DELISTED
Generation Bio
GBIO
$44.5M 0.36%
+211,882
New +$47.2M
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.99B
$44.1M 0.35%
2,500,000
+1,000,000
+67% +$12.5M
EFX icon
57
Equifax
EFX
$22.6B
$43.9M 0.35%
255,344
-122,931
-32% -$18.2M
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$42.7M 0.34%
715,000
-285,000
-29% -$15.2M
UTHR icon
59
United Therapeutics
UTHR
$22B
$42.4M 0.34%
350,000
-15,000
-4% -$1.69M
TVRD
60
Tvardi Therapeutics
TVRD
$24.8M
$39.3M 0.31%
63,889
– –
LNTH icon
61
Lantheus
LNTH
$6.53B
$37.7M 0.3%
+2,634,999
New +$34.8M
CYTK icon
62
Cytokinetics
CYTK
$10.7B
$35.4M 0.28%
1,500,000
+875,000
+140% +$16.4M
SAGE
63
DELISTED
Sage Therapeutics
SAGE
$35.3M 0.28%
850,000
+175,000
+26% +$6.35M
ARWR icon
64
Arrowhead Research
ARWR
$12.3B
$34.6M 0.28%
800,000
-200,000
-20% -$7.06M
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$33.2M 0.27%
+1,844,757
New +$25.7M
AMRS
66
DELISTED
Amyris Inc.
AMRS
$29.9M 0.24%
+7,009,527
New +$23.3M
TGTX icon
67
TG Therapeutics
TGTX
$8.31B
$29.2M 0.23%
+1,500,000
New +$24.2M
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$28.6M 0.23%
2,100,000
+45,514
+2% +$627K
FSCT
69
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$27.7M 0.22%
1,305,000
+430,000
+49% +$11.7M
PLRX icon
70
Pliant Therapeutics
PLRX
$71.8M
$27.6M 0.22%
+850,801
New +$22.6M
TECX
71
Tectonic Therapeutic
TECX
$736M
$27.5M 0.22%
131,250
-12,500
-9% -$2.58M
KPTI icon
72
Karyopharm Therapeutics
KPTI
$44.5M
$25.3M 0.2%
89,000
– –
ADAP
73
DELISTED
Adaptimmune Therapeutics
ADAP
$25M 0.2%
+2,500,000
New +$15.7M
RCUS icon
74
Arcus Biosciences
RCUS
$3.86B
$24.7M 0.2%
+1,000,000
New +$27M
BRMK
75
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$22.6M 0.18%
2,391,536
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2020 Portfolio in Review

As of Q2 2020, Thomas Steyer held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in T-Mobile US worth $360M.

  • Thomas Steyer's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
  • Thomas Steyer added most to Blackstone in Q2 2020, an estimated $125M increase.
  • Thomas Steyer's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
  • Thomas Steyer fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
  • Thomas Steyer's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
  • Thomas Steyer opened 32 new positions and closed 18 in Q2 2020.
  • Thomas Steyer's portfolio value rose 7.2% quarter-over-quarter to $12.5B.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.